Skip to content

April 2026

Default mode network

What April 2026's 4 new studies found, synthesized from the papers below. All Default mode network research →

The synthesis

Synthesized from 4 studies in the library · AI-generated, grounded in the abstracts below

Found by searching the library for Default mode network, DMN, resting-state network, then ranked by relevance.

Research in April 2026 consistently finds that the default mode network (DMN) is suppressed or desynchronized across diverse altered states, including psychedelic therapy, the 'awakening' state, and transpersonal practices. Evidence comes from narrative reviews, a single-subject EEG case study, and a cross-sectional fMRI study, but the latter shows reduced DMN differentiation to emotional stimuli rather than outright suppression. The main caveat is the limited and heterogeneous evidence base, with no large-scale controlled trials specifically targeting DMN dynamics.

Confidence in the evidence

Low-Moderate
  • Only four studies were provided, with one being a single-subject case study (article_id: 29783) and two being narrative reviews (article_id: 27788, 27275) that synthesize existing literature rather than presenting new data.
  • The only original empirical study with a control group (article_id: 28038) is a cross-sectional fMRI design (N=67), which cannot establish causality and shows mixed DMN findings (reduced differentiation, not simple suppression).
  • All studies converge on DMN modulation as a key mechanism, but the direction and magnitude vary: reviews claim DMN suppression, while the fMRI study reports reduced emotional category differentiation in DMN nodes.
  • No study directly tests DMN changes in April 2026 as a primary outcome; the findings are derived from broader investigations of altered states.
How we rate confidence

Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.

Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.

Evidence by study

Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.

This review states that psychedelics downregulate the default mode network, allowing music to guide emotional processing and facilitate therapeutic breakthroughs.

narrative review

This case study reports that the 'awakening' state manifests as DMN inhibition, characterized by increased fast-wave activity and low amplitude, distinguishing it from drug-induced sedation.

case study Sample size: 1

This comprehensive review identifies DMN suppression or modulation as a converging neurobiological mechanism across diverse altered states of consciousness, including psychedelics, meditation, and hypnotherapy.

review

This fMRI study found that psychedelic users showed reduced differentiation between emotional categories in two DMN nodes (frontal medial cortex and precuneus), alongside enhanced threat processing and heightened responses to happy expressions.

cross-sectional fMRI study Sample size: 67

Points of agreement

  • All studies implicate DMN modulation as a key neural mechanism in altered states of consciousness.
  • Reviews and the case study converge on DMN suppression or inhibition as a common feature of psychedelic and awakening states.
  • The cross-sectional fMRI study also points to DMN involvement, though with a more nuanced finding of reduced emotional differentiation.

Conflicts

  • The reviews (article_id: 27788, 27275) and case study (article_id: 29783) describe DMN suppression as a clear effect, while the fMRI study (article_id: 28038) reports reduced DMN differentiation between emotional categories, not outright suppression.
  • The case study (article_id: 29783) distinguishes the awakening state from drug-induced sedation, whereas the reviews focus on psychedelic-induced DMN downregulation, potentially conflating different mechanisms.

Gaps

  • No study directly measures DMN activity in April 2026 as a primary endpoint; findings are secondary or derived from broader reviews.
  • The evidence lacks longitudinal or experimental designs to establish causality between DMN changes and clinical outcomes.
  • Sample sizes are small (single case, N=67) and populations are narrow (experienced users, one self-regulated subject), limiting generalizability.
  • Durability of DMN changes and dose-response relationships are not addressed in the provided studies.
Browse these studies in the library